Apricus Biosciences Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Apricus Biosciences

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Strong Long who wrote (1931)	5/10/2016 5:43:13 PM
From: mokelumne river	of 2026

After listening to Dr. Kim, it appears that he would like very much to have Vitaros available to prescribe...and I discount the fact that he has received money from the company as a researcher. The same applies to urologists like Erwin Goldstein. But if you asked me how are things going in Europe, I would not be able to provide a positive response. Why? Because things seem muddled by the issues at Sandoz (which are not clear to me except product is not being sold), by the departure of Takeda (why their lack of interest?), and by what I view as the lack of attention by Apricus to what has been going on in the EU. I recognize that up until 35 days ago Apricus was all about Fispemifene. But Vitaros sales in the EU, which were going to be paying the bills in the next couple of years, have seemingly been falling through the cracks. Vitaros sales in France seems to be a good story. The rest, meh. I recall that Pascoe told Eman that he was frustrated with Sandoz. So? I would like to see some discussion by the company on the EU front. Unfortunately, I suspect Pascoe (like Bassam before him) is helpless to do much of anything because of the contractual language with the partners.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next